Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BAD: a good therapeutic target?

Andrea B Motoyama1, Nancy E Hynes

  • 1Friedrich Miescher Institute, Basel, Switzerland.

Breast Cancer Research : BCR
|February 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal FGF23 signaling depends on redox protein Memo1 and promotes orthovanadate-sensitive protein phosphotyrosyl phosphatase activity.

Journal of cell communication and signaling·2022
Same author

Aberrant RET expression affects normal mammary gland post-lactation transition, enhancing cancer potential.

Disease models & mechanisms·2022
Same author

Elevated serum magnesium lowers calcification propensity in Memo1-deficient mice.

PloS one·2020
Same author

Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.

Journal of mammary gland biology and neoplasia·2020
Same author

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.

PloS one·2019
Same author

Renal Memo1 Differentially Regulates the Expression of Vitamin D-Dependent Distal Renal Tubular Calcium Transporters.

Frontiers in physiology·2018

Cancer cells often evade apoptosis, hindering treatment. A new study shows that ZD1839, an epidermal growth factor receptor (EGFR) inhibitor, can induce apoptosis in growth factor-dependent mammary cells, targeting the BAD protein.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Cancer treatment aims to eliminate tumor cells, but many malignant cells evade apoptosis, a key cell death pathway.
  • Resistance to apoptosis is a major challenge in cancer therapy, particularly in breast cancer.
  • Epidermal growth factor receptor (EGFR) signaling plays a significant role in breast cancer development and progression.

Purpose of the Study:

  • To investigate the role of epidermal growth factor receptor (EGFR) signaling in apoptosis evasion in cancer cells.
  • To evaluate the efficacy of ZD1839, a small-molecule EGFR inhibitor, in inducing apoptosis in growth factor-dependent mammary cells.
  • To identify the key molecular effectors involved in EGFR-targeted therapy-induced apoptosis.

Main Methods:

Related Experiment Videos

  • Utilized ZD1839, a small-molecule inhibitor targeting the epidermal growth factor receptor (EGFR).
  • Assessed the induction of apoptosis in mammary cells dependent on growth factors for survival.
  • Investigated the involvement of BCL-2 family members, specifically BAD, as effectors of EGFR-targeted therapy.

    • Main Results:

    • ZD1839 demonstrated the ability to induce apoptosis in growth factor-dependent mammary cells.
    • The epidermal growth factor receptor (EGFR) was identified as a critical target for inducing cell death in these cells.
    • BAD, a BCL-2 family member, was confirmed as a major effector in the apoptosis pathway triggered by EGFR inhibition.

    Conclusions:

    • Targeting the epidermal growth factor receptor (EGFR) with inhibitors like ZD1839 shows promise for overcoming apoptosis resistance in certain cancers.
    • The BAD protein is a key mediator of apoptosis induced by EGFR-targeted therapy.
    • These findings support the therapeutic potential of EGFR inhibitors in breast cancer treatment by re-sensitizing tumor cells to apoptosis.